When was Erasca founded?

Erasca was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Erasca located?

Erasca is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Erasca have?

As of Jun 30, 2026, the latest employee count at Erasca is 114.

Is Erasca a funded company?

Erasca is a funded company, having raised a total of $300M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 18, 2018.

When was the latest funding round of Erasca?

Erasca's latest funding was a $***** Post IPO round on Mar 27, 2024, with participation from 0 investor.

Where does Erasca rank among its competitors?

Erasca ranks 11th amongst 3289 active competitors, of which 1119 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Erasca?

Erasca's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Erasca - 2026 Company Profile, Team, Funding, Competitors & Financials

Erasca is a public company based in San Diego (United States), founded in 2018 by Jonathan Lim. It operates as a Developer of small molecule based therapeutics for cancer. Erasca has raised $300M in funding from investors like Arch Venture Partners, Cormorant Asset Management and Andreessen Horowitz. The company has 3289 active competitors, including 1119 funded and 775 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of small molecule based therapeutics for cancer. The company product candidates include naporafenib, ERAS-007, and ERAS-80 for the treatment of melanoma and tissue agnostic solid tumors

Website: erasca.com
Email ID: *****@erasca.com
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Public

Total Funding

$300M in 5 rounds

Latest Funding Round

Post IPO, Mar 27, 2024, $*****

Investors

Arch Venture Partners & 14 more

Ranked

11^th among 3289 active competitors

Employee Count

114 as on Jun 30, 2026

Investment & Acquisitions

Affini-T Therapeutics

Similar Companies

Jazz Pharmaceuticals & 2981 more

Exit Details

Public

View Erasca's full profile

Erasca is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Erasca, Inc. CIN: 831217027 , United States, Active	Dec 31, 2017	-	109 (As on Dec 31, 2024)	-

Erasca got listed on Jul 16, 2021.

Click here to take a look at Erasca's IPO in detail

Erasca has raised a total funding of $300M over 5 rounds. Its first funding round was on Dec 18, 2018. Erasca has 14 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Erasca:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 27, 2024	2618865	Post IPO	2168165	8840449	8269872	7452006
Aug 31, 2020	3532610	Series B	7241533	1923525	2616229	2872152
Apr 30, 2020	3376612	Series B	5442542	6255617	Arch Venture Partners & 1 more	TMCP & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Erasca's funding rounds and investors

The founders of Erasca is Jonathan Lim.

Here are the details of Erasca's key team members:

Jonathan Lim: Co-Founder, CEo & Chairman of Erasca and founder of 1 other company.

View details of Erasca's Founder profiles and Board Members

Erasca's employee count trend

Erasca has 114 employees as of Jun 26. Here is Erasca's employee count trend over the years:

Uncover Erasca's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Erasca include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Erasca, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
11th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Colt Ventures, Orbimed & 13 others	71/100